Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)

-- Three acute pivotal studies did not meet their primary endpoint ---- Interim analysis of relapse prevention study suggests the primary endpoint will not be met -

Allergan announces that they "are deeply disappointed with the Phase III trials of Rapastinel" Rapastinel failed to meet the study end points in three Phase III clinical trials The good news is that there is an NMDA modulator (Ketamine) that works and it is available to patients right now!!